The world’s first comprehensive
genetic screen for reproductive health
Defining a new category of genetic tests
Unlike carrier screening tests, which look at the health risks for a baby, the Fertilome test is the first genetic screen that examines a woman’s genetic signature and how it may impact her reproductive health and ability to conceive, today and in the future.
How the Fertilome test can work for you
By revealing genetic risk factors, the Fertilome test enables more refined diagnoses and treatment decisions than physical examinations or existing diagnostic tests alone. Using the genetic test can help you frame conversations around reproductive health and family building as a proactive journey.
Identify subclinical factors
Refine treatment plans
Counsel women with family history
Counsel egg freezing candidates
Guide targeted lifestyle counseling
The science behind our test
The Fertilome test analyzes 49 variants in 32 genes associated with a spectrum of female reproductive conditions. The Fertilome panel was developed through a systematic literature review and statistical meta-analysis.
Take the next step
1. https://clinicalgenome.org/site/assets/ les/2657/current_clinical_validity_classi cations.pdf
2. The Fertilome test only includes genetic variants that meet the American College of Medical Genetics and Genomics (ACMG) and American Pathology (AMP) 2015 guidelines for pathogenicity of a genetic marker.
MacArthur, DG. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014; 508:469-476.
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405-423.
3. Celmatix is accredited by the College of American Pathologists (CAP), is permitted by New York State Clinical Laboratory Evaluation Program (CLEP) to perform molecular genetic testing, and therefore is authorized by Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
4. Each Fertilome test request must be independently approved by the Department. Department approval should not be considered as an endorsement of CCL's competence; or that CCL has complied with all relevant federal and/or state regulations. The Fertilome genetic test is not currently approved by the Department and is not subjected to approval by the U.S. Food and Drug Administration.